Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably more when the injectable treatment was obtained at pharmacies rather than injected in ...

Please provide your email address to receive an email when new articles are posted on . In 2026, Stelara will be discounted 66% from its list price for Medicare users, while Enbrel will be discounted ...

Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...

Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Pharmacy benefit managers take different approaches to controlling ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the steady ...

J&J seeks preliminary injunction over Samsung's sublicense deal with private label provider J&J says said sublicense deal would hurt its market share Samsung Bioepis launched its biosimilar in U.S. on ...